Carrie W. Rinker-Schaeffer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Carrie W. Rinker-Schaeffer has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Robert Clark
Section of Urology, Department of Surgery, The University of Chicago
5 shared publicationsJonathan Hickson
Abbot Laboratories
4 shared publications- Tamara Levin Lotan
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
4 shared publications Kristen Otto
Department of Surgery, Section of Urology, The University of Chicago, Chicago, IL
3 shared publicationsShaheena Khan
The University of Chicago
3 shared publicationsVenkatesh Krishnan
Section of Urology, Department of Surgery, The University of Chicago
3 shared publications
Latest Publications
- Open Access
- 14 October 2015
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 104,p. e52721
In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
We outline a protocol that implements both in vivo and ex vivo approaches to study ovarian cancer colonization of...
- 14 October 2015
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 104,p. e52721
Open AccessIn Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
We outline a protocol that implements both in vivo and ex vivo approaches to study ovarian cancer colonization of...
- Open Access
- 1 August 2013
- Published by Elsevier in The American Journal of Pathology
- Vol. 183 (2) , 576-591
Milky Spots Promote Ovarian Cancer Metastatic Colonization of Peritoneal Adipose in Experimental Models
- 1 August 2013
- Published by Elsevier in The American Journal of Pathology
- Vol. 183 (2) , 576-591
Open AccessMilky Spots Promote Ovarian Cancer Metastatic Colonization of Peritoneal Adipose in Experimental Models
- 17 June 2012
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 31 (3-4) , 605-613
Using MKK4’s metastasis suppressor function to identify and dissect cancer cell–microenvironment interactions during metastatic colonization
Host tissue microenvironment plays key roles in cancer progression and colonization of secondary organs. One example is ovarian cancer, which colonizes the peritoneal cavity and especially the omentum. Our research indicates that the interaction of ovarian cancer cells with the omental microenvironment can activate a stress-kinase pathway involving the mitogen-activated protein kinase kinase 4 (MKK4). A combination of clinical correlative and functional data suggests that MKK4 activation suppresses growth of ovarian cancer cells lodged in omentum. These findings prompted us to turn our focus to the cellular composition of the omental microenvironment and its role in regulating cancer growth. In this review, in addition to providing an overview of MKK4 function, we highlight a use for metastasis suppressors as a molecular tool to study cancer cell interaction with its microenvironment. We review features of the omentum that makes it a favorable microenvironment for metastatic colonization. In conclusion, a broader, evolutionary biology perspective is presented which we believe needs to be considered when studying the evolution of cancer cells within a defined microenvironment. Taken together, this approach can direct new multi-dimensional lines of research aimed at a mechanistic understanding of host tissue microenvironment, which could be used to realize novel targets for future research.
- 17 June 2012
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 31 (3-4) , 605-613
Using MKK4’s metastasis suppressor function to identify and dissect cancer cell–microenvironment interactions during metastatic colonization
Host tissue microenvironment plays key roles in cancer progression and colonization of secondary organs. One example is ovarian cancer, which colonizes the peritoneal cavity and especially the omentum. Our research indicates that the interaction of ovarian cancer cells with the omental microenvironment can activate a stress-kinase pathway involving the mitogen-activated protein kinase kinase 4 (MKK4). A combination of clinical correlative and functional data suggests that MKK4 activation suppresses growth of ovarian cancer cells lodged in omentum. These findings prompted us to turn our focus to the cellular composition of the omental microenvironment and its role in regulating cancer growth. In this review, in addition to providing an overview of MKK4 function, we highlight a use for metastasis suppressors as a molecular tool to study cancer cell interaction with its microenvironment. We review features of the omentum that makes it a favorable microenvironment for metastatic colonization. In conclusion, a broader, evolutionary biology perspective is presented which we believe needs to be considered when studying the evolution of cancer cells within a defined microenvironment. Taken together, this approach can direct new multi-dimensional lines of research aimed at a mechanistic understanding of host tissue microenvironment, which could be used to realize novel targets for future research.
- 21 February 2012
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 29 (5) , 397-408
Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization
Although metastasis is the most lethal attribute of cancer, critical gaps in our knowledge of how cancer cells effectively colonize distant sites remain. For example, little is known about the cellular and molecular events that occur during the timecourse of metastatic colonization. To address this we are using the mitogen-activated protein kinase kinase 4 (MKK4) metastasis suppressor as a tool to identify these events. Specifically, we report a microarray expression-based strategy to identify genes whose transcription is altered in SKOV3ip.1 human ovarian cancer cells that express ectopic MKK4 throughout the course of in vivo metastatic colonization. The majority of genes identified fell into the categories of cytokinesis, cytoskeleton remodeling, and cell adhesion, and their expression was repressed in MKK4-expressing cells relative to vector controls. The greatest transcriptional divergence was concomitant with impaired proliferation at 14 days post injection (dpi). Specifically, 763 genes were differentially expressed (FDR < 0.05) between lesions that expressed ectopic MKK4 and paired controls. In contrast, only seven genes were differentially expressed at the experimental endpoint, when MKK4-expressing and control cells had formed macroscopic metastases. Application of our cohort of differentially expressed genes to three independent clinical datasets demonstrated a strong correlation between our findings and metastatic phenotypes in patient samples. Our results highlight the dynamic nature of metastatic colonization and reinforce the importance of examining both molecular and cellular phenotypes over time when studying metastasis formation.
- 21 February 2012
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 29 (5) , 397-408
Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization
Although metastasis is the most lethal attribute of cancer, critical gaps in our knowledge of how cancer cells effectively colonize distant sites remain. For example, little is known about the cellular and molecular events that occur during the timecourse of metastatic colonization. To address this we are using the mitogen-activated protein kinase kinase 4 (MKK4) metastasis suppressor as a tool to identify these events. Specifically, we report a microarray expression-based strategy to identify genes whose transcription is altered in SKOV3ip.1 human ovarian cancer cells that express ectopic MKK4 throughout the course of in vivo metastatic colonization. The majority of genes identified fell into the categories of cytokinesis, cytoskeleton remodeling, and cell adhesion, and their expression was repressed in MKK4-expressing cells relative to vector controls. The greatest transcriptional divergence was concomitant with impaired proliferation at 14 days post injection (dpi). Specifically, 763 genes were differentially expressed (FDR < 0.05) between lesions that expressed ectopic MKK4 and paired controls. In contrast, only seven genes were differentially expressed at the experimental endpoint, when MKK4-expressing and control cells had formed macroscopic metastases. Application of our cohort of differentially expressed genes to three independent clinical datasets demonstrated a strong correlation between our findings and metastatic phenotypes in patient samples. Our results highlight the dynamic nature of metastatic colonization and reinforce the importance of examining both molecular and cellular phenotypes over time when studying metastasis formation.
- 12 September 2011
- Published by Wiley in FEBS Letters
- Vol. 585 (20) , 3159-3165
Building on the foundation of daring hypotheses: Using the MKK4 metastasis suppressor to develop models of dormancy and metastatic colonization
The identification of a novel metastasis suppressor function for the MAP Kinase Kinase 4 protein established a role for the stress-activated kinases in regulating the growth of disseminated cancer cells. In this review, we describe MKK4's biological mechanism of action and how this information is being used to guide the development of new models to study cancer cell dormancy and metastatic colonization. Specifically, we describe the novel application of microvolume structures, which can be modified to represent characteristics similar to those that cancer cells experience at metastatic sites. Although MKK4 is currently one of many known metastasis suppressors, this field of research started with a single daring hypothesis, which revolutionized our understanding of metastasis, and opened up new areas of exploration for basic research. The combination of our increasing knowledge of metastasis suppressors and such novel technologies provide hope for possible clinical interventions to prevent suffering from the burden of metastatic disease. (C) 2011 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
- 12 September 2011
- Published by Wiley in FEBS Letters
- Vol. 585 (20) , 3159-3165
Building on the foundation of daring hypotheses: Using the MKK4 metastasis suppressor to develop models of dormancy and metastatic colonization
The identification of a novel metastasis suppressor function for the MAP Kinase Kinase 4 protein established a role for the stress-activated kinases in regulating the growth of disseminated cancer cells. In this review, we describe MKK4's biological mechanism of action and how this information is being used to guide the development of new models to study cancer cell dormancy and metastatic colonization. Specifically, we describe the novel application of microvolume structures, which can be modified to represent characteristics similar to those that cancer cells experience at metastatic sites. Although MKK4 is currently one of many known metastasis suppressors, this field of research started with a single daring hypothesis, which revolutionized our understanding of metastasis, and opened up new areas of exploration for basic research. The combination of our increasing knowledge of metastasis suppressors and such novel technologies provide hope for possible clinical interventions to prevent suffering from the burden of metastatic disease. (C) 2011 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
- 26 April 2011
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 8 (6) , 333-342
Metastasis-suppressor genes in clinical practice: lost in translation?
Metastasis-suppressor genes (MSGs) are involved in diverse molecular processes in multiple tumor types; therefore, treatment strategies based on MSGs have unparalleled potential to improve patient care. In this Review, barriers specific to the translation of MSG biology into clinical practice are discussed and future research directions necessary for clinical advances are delineated. Over the past 25 years, an expanding set of metastasis-suppressor genes (MSGs) has been identified that specifically regulate metastasis formation without affecting primary growth. MSGs are involved in diverse molecular processes in multiple tumor types. Given the wealth of metastasis biology that underlies their functions, treatment strategies based on MSGs have an unparalleled potential to improve patient care. Using NM23 as a prime example, we discuss how specific MSGs have been used as prognostic markers, tools for predicting response to treatment, and targets for the development of novel therapies. Barriers specific to the translation of MSG biology into clinical practice are reviewed and future research directions necessary for clinical advances are delineated. Although to date the impact of MSGs on patient care is limited, it is an expanding field with vast potential to help develop new treatments and identify patients who will most benefit from them.
- 26 April 2011
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 8 (6) , 333-342
Metastasis-suppressor genes in clinical practice: lost in translation?
Metastasis-suppressor genes (MSGs) are involved in diverse molecular processes in multiple tumor types; therefore, treatment strategies based on MSGs have unparalleled potential to improve patient care. In this Review, barriers specific to the translation of MSG biology into clinical practice are discussed and future research directions necessary for clinical advances are delineated. Over the past 25 years, an expanding set of metastasis-suppressor genes (MSGs) has been identified that specifically regulate metastasis formation without affecting primary growth. MSGs are involved in diverse molecular processes in multiple tumor types. Given the wealth of metastasis biology that underlies their functions, treatment strategies based on MSGs have an unparalleled potential to improve patient care. Using NM23 as a prime example, we discuss how specific MSGs have been used as prognostic markers, tools for predicting response to treatment, and targets for the development of novel therapies. Barriers specific to the translation of MSG biology into clinical practice are reviewed and future research directions necessary for clinical advances are delineated. Although to date the impact of MSGs on patient care is limited, it is an expanding field with vast potential to help develop new treatments and identify patients who will most benefit from them.
- 1 April 2011
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 21 (2) , 89-98
Thinking outside the box: Using metastasis suppressors as molecular tools
- 1 April 2011
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 21 (2) , 89-98
Thinking outside the box: Using metastasis suppressors as molecular tools
- Open Access
- 23 February 2011
- Published by Wiley in International Journal of Cancer
- Vol. 130 (3) , 509-520
MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression
Metastatic dissemination in prostate cancer is often early, but not all cancer cells form clinical metastases. Map kinase kinase 4 (MKK4) suppresses metastasis in a preclinical prostate cancer model. We hypothesize that MKK4 will specifically inhibit metastatic colonization through impaired proliferation. Three highly metastatic rat prostate cancer cell lines (AT6.1, Mat‐Lu and AT3.1) were employed. Stably over‐expressing HA‐MKK4 or vector control lines were injected into immunocompromised mice. These experiments validated that HA‐MKK4 specifically affects metastatic colonization and increases survival. Median survival (days) with HA‐MKK4 vs. vector was 42 vs. 28 (p < 0.0001) for AT6.1, 25 vs. 19 (p < 0.0001) for Mat‐Lu and 27 vs. 20 (p < 0.0001) for AT3.1. HA‐MKK4 suppresses colonization within 14 days post dissemination, after which exponential proliferation resumes. Although overt metastases retain HA‐MKK4, it is inactive within these lesions. Nonetheless, metastasis‐derived cell lines were shown to retain functional HA‐MKK4 and like their parental HA‐MKK4 line are suppressed for experimental metastasis formation in vivo. Disseminated AT6.1‐HA‐MKK4 cells were analyzed and were found to have an alteration in cell cycle. Specifically, there was an accumulation of cells in G1‐phase (p = 0.024) and decrease in S‐phase (p = 0.037) compared with vector. In multiple prostate cancer lines, HA‐MKK4 suppresses an early step in metastatic colonization. These data support a model in which MKK4 activation at the metastatic site causes a cell‐cycle arrest, which is eventually overcome despite presence of functional HA‐MKK4. Further studies will specifically interrogate the regulation of MKK4 activation within the metastatic microenvironment and the down‐stream molecular events critical for metastasis suppression.
- 23 February 2011
- Published by Wiley in International Journal of Cancer
- Vol. 130 (3) , 509-520
Open AccessMKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression
Metastatic dissemination in prostate cancer is often early, but not all cancer cells form clinical metastases. Map kinase kinase 4 (MKK4) suppresses metastasis in a preclinical prostate cancer model. We hypothesize that MKK4 will specifically inhibit metastatic colonization through impaired proliferation. Three highly metastatic rat prostate cancer cell lines (AT6.1, Mat‐Lu and AT3.1) were employed. Stably over‐expressing HA‐MKK4 or vector control lines were injected into immunocompromised mice. These experiments validated that HA‐MKK4 specifically affects metastatic colonization and increases survival. Median survival (days) with HA‐MKK4 vs. vector was 42 vs. 28 (p < 0.0001) for AT6.1, 25 vs. 19 (p < 0.0001) for Mat‐Lu and 27 vs. 20 (p < 0.0001) for AT3.1. HA‐MKK4 suppresses colonization within 14 days post dissemination, after which exponential proliferation resumes. Although overt metastases retain HA‐MKK4, it is inactive within these lesions. Nonetheless, metastasis‐derived cell lines were shown to retain functional HA‐MKK4 and like their parental HA‐MKK4 line are suppressed for experimental metastasis formation in vivo. Disseminated AT6.1‐HA‐MKK4 cells were analyzed and were found to have an alteration in cell cycle. Specifically, there was an accumulation of cells in G1‐phase (p = 0.024) and decrease in S‐phase (p = 0.037) compared with vector. In multiple prostate cancer lines, HA‐MKK4 suppresses an early step in metastatic colonization. These data support a model in which MKK4 activation at the metastatic site causes a cell‐cycle arrest, which is eventually overcome despite presence of functional HA‐MKK4. Further studies will specifically interrogate the regulation of MKK4 activation within the metastatic microenvironment and the down‐stream molecular events critical for metastasis suppression.
- Open Access
From Prostate to Bone: Key Players in Prostate Cancer Bone Metastasis
Bone is the most common site for metastasis in human prostate cancer patients. Skeletal metastases are a significant cause of morbidity and mortality and overall greatly affect the quality of life of prostate cancer patients. Despite advances in our understanding of the biology of primary prostate tumors, our knowledge of how and why secondary tumors derived from prostate cancer cells preferentially localize bone remains limited. The physiochemical properties of bone, and signaling molecules including specific chemokines and their receptors, are distinct in nature and function, yet play intricate and significant roles in prostate cancer bone metastasis. Examining the impact of these facets of bone metastasis in vivo remains a significant challenge, as animal models that mimic the natural history and malignant progression clinical prostate cancer are rare. The goals of this article are to discuss (1) characteristics of bone that most likely render it a favorable environment for prostate tumor cell growth, (2) chemokine signaling that is critical in the recruitment and migration of prostate cancer cells to the bone, and (3) current animal models utilized in studying prostate cancer bone metastasis. Further research is necessary to elucidate the mechanisms underlying the extravasation of disseminated prostate cancer cells into the bone and to provide a better understanding of the basis of cancer cell survival within the bone microenvironment. The development of animal models that recapitulate more closely the human clinical scenario of prostate cancer will greatly benefit the generation of better therapies.
Open AccessFrom Prostate to Bone: Key Players in Prostate Cancer Bone Metastasis
Bone is the most common site for metastasis in human prostate cancer patients. Skeletal metastases are a significant cause of morbidity and mortality and overall greatly affect the quality of life of prostate cancer patients. Despite advances in our understanding of the biology of primary prostate tumors, our knowledge of how and why secondary tumors derived from prostate cancer cells preferentially localize bone remains limited. The physiochemical properties of bone, and signaling molecules including specific chemokines and their receptors, are distinct in nature and function, yet play intricate and significant roles in prostate cancer bone metastasis. Examining the impact of these facets of bone metastasis in vivo remains a significant challenge, as animal models that mimic the natural history and malignant progression clinical prostate cancer are rare. The goals of this article are to discuss (1) characteristics of bone that most likely render it a favorable environment for prostate tumor cell growth, (2) chemokine signaling that is critical in the recruitment and migration of prostate cancer cells to the bone, and (3) current animal models utilized in studying prostate cancer bone metastasis. Further research is necessary to elucidate the mechanisms underlying the extravasation of disseminated prostate cancer cells into the bone and to provide a better understanding of the basis of cancer cell survival within the bone microenvironment. The development of animal models that recapitulate more closely the human clinical scenario of prostate cancer will greatly benefit the generation of better therapies.
- Open Access
- 14 March 2010
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2010, 1-7
Disrupting Ovarian Cancer Metastatic Colonization: Insights from Metastasis Suppressor Studies
Ovarian cancer affects approximately 25,000 women in the United States each year and remains one of the most lethal female malignancies. A standard approach to therapy is surgical cytoreduction, after which the remaining microscopic residual disease is treated with chemotherapy. The vast majority of patients have disease recurrence, underscoring the crucial need for approaches to control the regrowth, or colonization, of tissues after local treatment. Improved therapies require mechanistic information about the process of metastatic colonization, the final step in metastasis, in which cancer cells undergo progressive growth at secondary sites. Studies of metastasis suppressors are providing insights into events controlling metastatic colonization. This paper reviews our laboratory's approach to the identification, characterization, and functional testing of the JNKK1/MKK4 metastasis suppressor in ovarian cancer metastatic colonization. Specifically, we demonstrate that interaction of ovarian caner cells with the omental microenvironment activates JNKK1/MKK4 resulting in decreased proliferation without affecting apoptosis. The potential role of the omental microenvironment, specifically milky spot structures, is also described. It is our goal to provide this work as a usable paradigm that will enable others to study metastasis suppressors in clinical and experimental ovarian cancer metastases.
- 14 March 2010
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2010, 1-7
Open AccessDisrupting Ovarian Cancer Metastatic Colonization: Insights from Metastasis Suppressor Studies
Ovarian cancer affects approximately 25,000 women in the United States each year and remains one of the most lethal female malignancies. A standard approach to therapy is surgical cytoreduction, after which the remaining microscopic residual disease is treated with chemotherapy. The vast majority of patients have disease recurrence, underscoring the crucial need for approaches to control the regrowth, or colonization, of tissues after local treatment. Improved therapies require mechanistic information about the process of metastatic colonization, the final step in metastasis, in which cancer cells undergo progressive growth at secondary sites. Studies of metastasis suppressors are providing insights into events controlling metastatic colonization. This paper reviews our laboratory's approach to the identification, characterization, and functional testing of the JNKK1/MKK4 metastasis suppressor in ovarian cancer metastatic colonization. Specifically, we demonstrate that interaction of ovarian caner cells with the omental microenvironment activates JNKK1/MKK4 resulting in decreased proliferation without affecting apoptosis. The potential role of the omental microenvironment, specifically milky spot structures, is also described. It is our goal to provide this work as a usable paradigm that will enable others to study metastasis suppressors in clinical and experimental ovarian cancer metastases.